Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Empagliflozin is a prescription sodium-glucose cotransporter 2 inhibitor and the active ingredient in Jardiance. It is used for type 2 diabetes from age 10 and for several adult cardiovascular and kidney indications. Tablets come in 10 mg and 25 mg strengths and are taken once daily.
read more about empagliflozin ...SGLT2 is the main transporter responsible for returning filtered glucose from the kidney tubules to the bloodstream. Empagliflozin inhibits SGLT2, reduces renal glucose reabsorption, lowers the kidney threshold for glucose, and increases urinary glucose excretion.
Empagliflozin improves glycemic control in adults and children age 10 and older with type 2 diabetes. In adults, it also reduces cardiovascular death and heart failure hospitalization in heart failure, reduces selected kidney and cardiovascular outcomes in chronic kidney disease at risk of progression, and reduces cardiovascular death in type 2 diabetes with established cardiovascular disease.
The recommended dose is 10 mg once daily in the morning with or without food. For additional glycemic control, the dose can increase to 25 mg once daily in patients who tolerate 10 mg. The 25 mg dose increase applies to glycemic control rather than the heart failure or chronic kidney disease indications.
Serious concerns include ketoacidosis, volume depletion, urosepsis, pyelonephritis, Fournier gangrene, genital fungal infections, hypoglycemia with selected diabetes therapies, lower-limb amputation, and hypersensitivity. Empagliflozin is withheld for at least three days before surgery or procedures involving prolonged fasting when possible.
Yes. Empagliflozin blocks SGLT2 in the kidney and increases urinary glucose excretion.
Empagliflozin is taken once daily in the morning with or without food.
Yes. Current U.S. labeling includes glycemic treatment from age 10.
The labeled adult dose for heart failure is 10 mg once daily.
Empagliflozin. https://pubmed.ncbi.nlm.nih.gov/30422520/. Date Accessed September 29, 2026.
Empagliflozin: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a614043.html. Date Accessed September 29, 2026.
JARDIANCE (Empagliflozin) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=faf3dd6a-9cd0-39c2-0d2e-232cb3f67565. Date Accessed September 29, 2026.
JARDIANCE (Empagliflozin) Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204629s063lbl.pdf. Date Accessed September 29, 2026.
Jardiance (Empagliflozin) Tablets Supplement Approval. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204629Orig1s040ltr.pdf. Date Accessed September 29, 2026.